Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, equitable care strategies and tailored treatment approaches.
The team discovered a unique population of immune cells that is important to the successful treatment of relapsed acute myeloid leukemia (AML). This investigation was done in partnership with the ...
Tumor-Induced B Cell Changes Reveal Potential Biomarker for Treatment Response in Triple ... has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth.
Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments.